Cargando…
Are we closer to being able to select patients with node-positive hormone receptor-positive breast cancer who can safely omit chemotherapy?
The treatment of hormone receptor-positive, HER2-negative breast cancer has become increasingly individualized, thanks to the development of genomic testing. Gene expression assays provide clinicians and patients with both prognostic and predictive information regarding breast cancer recurrence risk...
Autores principales: | Taylor, Caitlin, Meisel, Jane, Kalinsky, Kevin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958684/ https://www.ncbi.nlm.nih.gov/pubmed/35356261 http://dx.doi.org/10.1177/17588359221084769 |
Ejemplares similares
-
Could axillary lymph node dissection be omitted in the mastectomy patient with tumor positive sentinel node?
por: You, Ji Young, et al.
Publicado: (2023) -
SAFE™ Initiative: A Step Closer to Positive Safety Culture and Improved Patient Experience
por: Plouff, Cherie, et al.
Publicado: (2022) -
Adjuvant therapy may be omitted for oral cavity cancer with only one positive lymph node
por: Chen, Wan‐Yu, et al.
Publicado: (2021) -
A Nomogram for Identifying HR+/Her2− Breast Cancer Patients with Positive Sentinel Lymph Nodes and Omitted Axillary Lymph Node Dissection Who Need Abemaciclib Therapy
por: Yang, Hanzhao, et al.
Publicado: (2023) -
Can Axillary Lymph Node Dissection Be Safely Omitted for Early-Stage Breast Cancer Patients with Sentinel Lymph Node Micrometastasis?
por: Damle, Sameer, et al.
Publicado: (2009)